Format

Send to

Choose Destination
Vaccine. 2009 Nov 5;27(47):6504-11. doi: 10.1016/j.vaccine.2009.07.076. Epub 2009 Aug 7.

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile.

Author information

1
Vaccination Outpatient Clinic, Szpital sw. Ludwika, ul. Strzelecka 2, 31-503 Cracow, Poland. hanna.czajka@neostrada.pl

Erratum in

  • Vaccine. 2010 Dec 6;28(52):8352.
  • Vaccine. 2012 Dec 14;30(52):7667.

Abstract

Priorix-Tetra (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix) and varicella (Varilrix) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.

PMID:
19665608
DOI:
10.1016/j.vaccine.2009.07.076
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center